Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289557 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
A Phase 3 study of Morning Sickness, sponsored by Duchesnay.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
- 10
- Study locations
NCT05289557: Recruiting Phase 3 study of Morning Sickness, sponsored by Duchesnay.
NCT05289557 is a Phase 3 study of Morning Sickness that is actively recruiting participants, run by Duchesnay. The registered enrollment target is 274 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05289557, a Phase 3 study of Morning Sickness, is actively recruiting participants, sponsored by Duchesnay.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of this study is to compare the efficacy of Bonjesta for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo. The secondary objective of this study is to compare the safety of Bonjesta in pregnant adolescents aged 12 to 17 years with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bonjesta
Study Locations (10)
Florida
- Vital Pharma Research - Hialeah
- New Horizon Research Center - Miami
- Emerald Coast OB/GYN Clinical Research - Panama City
Texas
- Maximos OBGYN - League City
- Axon Clinical Research - Mesquite
- Advances in Health - Pearland
California
- Velvet Clinical Research - Burbank
Idaho
- Clinical Research Prime - Idaho Falls
North Carolina
- Unified Women's Clinical Research - Winston-Salem
South Carolina
- Clinovacare Medical Research Center - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT05289557 shows while recruiting
NCT05289557 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Morning Sickness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05289557 lists 10 locations in 6 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT05289557 about?
NCT05289557 is a clinical study titled "The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents". The primary objective of this study is to compare the efficacy of Bonjesta for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo. The secondary objective of this study is to compare the safety of Bonjesta in pregnant adolescents aged 12...
What is the current status of trial NCT05289557?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2022-05-01. Estimated completion is 2027-12.
What conditions does trial NCT05289557 study?
This clinical trial studies the following conditions: Morning Sickness.
What interventions are being tested in trial NCT05289557?
The interventions under investigation include: Placebo (DRUG), Bonjesta (DRUG).
Who is sponsoring clinical trial NCT05289557?
This trial is sponsored by Duchesnay, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05289557 being conducted?
This trial has 10 study locations across California, Florida, Idaho, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05289557's enrollment target sits among peer trials
274 1208th of 2000 higher than 788 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
- NCT06173401 · 274 participants · Phase 3
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI